Bordetella species in children with cystic fibrosis: What do we know?. The role in acute exacerbations and chronic course

Journal of Cystic Fibrosis

Volumn 10, Issue 5, 2011, Pages 307-312

  Bos, A C ^a   Beemsterboer, P ^b   Wolfs, T F W ^a   Versteegh, F G A ^b   Arets, H G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GROENE HART HOSPITAL   (Netherlands)

Author keywords

Bordetella; Cystic fibrosis; Pertussis

Indexed keywords

BACTERIUM DETECTION; BACTERIUM ISOLATION; BORDETELLA; BORDETELLA AVIUM; BORDETELLA BRONCHISEPTICA; BORDETELLA BRONCHISEPTICA INFECTION; BORDETELLA HINZII; BORDETELLA PARAPERTUSSIS; BORDETELLA PARAPERTUSSIS INFECTION; BORDETELLA PERTUSSIS; BORDETELLA PETRII; CHLAMYDIAL PNEUMONIA; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; MORBIDITY; MYCOPLASMA PNEUMONIA; NONHUMAN; PERTUSSIS; PROGRESSION FREE SURVIVAL; REVIEW; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW;

ACUTE DISEASE; BORDETELLA; BORDETELLA INFECTIONS; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; INCIDENCE; WHOOPING COUGH;

EID: 80052453179     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.06.003     Document Type: Review

References (28)

1. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax Apr. 2007, 62(4):360-367.
2. Coenye T., Goris J., Spilker T., Vandamme P., LiPuma J.J. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol Jun. 2002, 40(6):2062-2069.
3. Ner Z., Ross L.A., Horn M.V., Keens T.G., MacLaughlin E.F., Starnes V.A., et al. Bordetella bronchiseptica infection in pediatric lung transplant recipients. Pediatr Transplant Oct. 2003, 7(5):413-417.
4. Spilker T., Liwienski A.A., LiPuma J.J. Identification of Bordetella spp. in respiratory specimens from individuals with cystic fibrosis. Clin Microbiol Infect May 2008, 14(5):504-506.
5. Wallet F., Perez T., Armand S., Wallaert B., Courcol R.J. Pneumonia due to Bordetella bronchiseptica in a cystic fibrosis patient: 16S rRNA sequencing for diagnosis confirmation. J Clin Microbiol Jun. 2002, 40(6):2300-2301.
6. Funke G., Hess T., von Graevenitz A., Vandamme P. Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period. J Clin Microbiol Apr. 1996, 34(4):966-969.
7. Fry N., Duncan J., Harrison T. Identification and significance of Bordetella species, other than B. pertussis and B. parapertussis in the UK. Eighth international symposium: sage of the genus Bordetella, November 7-10, 2006, Paris, France 2006, 7-11-2006.
8. de Greeff S.C., de Melker H.E., van Gageldonk P.G.M., Schellekens J.F.P., van der Klis F.R.M., Mollema L., et al. Seroprevalence of pertussis in the Netherlands: Evidence for increased circulation of Bordetella pertussis. PLoS One Dec. 1 2010, 5(12):e14183. 10.1371/journal.pone.0014183.
9. Olesen H.V., Nielsen L.P., Schiotz P.O. Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr Pulmonol Dec. 2006, 41(12):1197-1204.
10. Riffelmann M., Wirsing von König C.H., Caro V., Guiso N. Nucleic acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol Oct. 2005, 43(10):4925-4929.
11. Guiso N., Berbers G., Fry N.K., He Q., Riffelmann M., Wirsing von König C.H. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis Mar. 2011, 30(3):307-312.
12. de Melker H.E., Versteegh F.G.A., Schellekens J.F.P., Teunis P.F.M., Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect Aug. 2006, 53(2):106-113.
13. de Greeff S.C., de Melker H.E., Mooi F.R. Pertussis in the Netherlands: the consequences of changes in the vaccination schedule with regards to the incidence of the disease and its pathogen. Infectieziekten Bull 2007, 18(5):175-179.
14. Halperin S.A. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J Jun. 2005, 24(6 Suppl.):S141-S146.
15. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev Apr. 2005, 18(2):326-328.
16. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med Nov. 15 2007, 176(10):957-969.
17. Tazumi A., Maeda Y., Goldsmith C.E., Coulter W.A., Mason C., Millar B.C., et al. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group Streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J Antimicrob Chemother Sep. 2009, 64(3):501-506.
18. Robay A., Toumaniantz G., Leblais V., Gauthier C. Transfected beta3- but not beta2-adrenergic receptors regulate cystic fibrosis transmembrane conductance regulator activity via a new pathway involving the mitogen-activated protein kinases extracellular signal-regulated kinases. Mol Pharmacol Mar. 2005, 67(3):648-654.
19. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros Nov. 30 2007, 6(6):403-410.
20. Kendirli S.G., Yilmaz M., Bayram I., Altintas D.U., Inal A., Karakoc G. Potential association between allergic diseases and pertussis infection in schoolchildren: results of two cross-sectional studies seven years apart. Allergol Immunopathol (Madr) Jan-Feb. 2009, 37(1):21-25.
21. Bernsen R.M., Nagelkerke N.J., Thijs C., van der Wouden J.C. Reported pertussis infection and risk of atopy in 8- to 12-yr-old vaccinated and non-vaccinated children. Pediatr Allergy Immunol 2008, 19(1):46-52.
22. Al-Mousawi M.S., Lovel H., Behbehani N., Arifhodzic N., Woodcock A., Custovic A. Asthma and sensitization in a community with low indoor allergen levels and low pet-keeping frequency. J Allergy Clin Immunol 2004, 114(6):1389-1394.
23. El-Sharif N., Abdeen Z., Barghuthy F., Nemery B. Familial and environmental determinants for wheezing and asthma in a case control study of school children in Palestine. Clin Exp Allergy 2003, 33(2):176-186.
24. Nilsson L., Kjellman N.I., Bjorksten B. A randomized controlled trial of the effect of pertussis vaccines on atopic disease. Arch Pediatr Adolesc Med 1998, 152(8):734-738.
25. Waked M, Salameh P. Risk factors for asthma and allergic diseases in school children across Lebanon. Journal of Asthma and Allergy 2008;2009:2.
26. Cagney M., MacIntyre C.R., McIntyre P.B., Peat J. Childhood asthma diagnosis and use of asthma medication. Aust Fam Physician 2005, 34(3):193-196.
27. Ennis D.P., Cassidy J.P., Mahon B.P. Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma. Clin Exp Allergy 2004, 34(9):1488-1497.
28. Harju T.H., Leinonen M., Nokso-Koivisto J., Korhonen T., Raty R., He Q., et al. Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma. Thorax 2006, 61(7):579-584.